

Sandro S Santagata

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5998326/publications.pdf>

Version: 2024-02-01

219
papers

20,365
citations

11639

70
h-index

12585

132
g-index

245
all docs

245
docs citations

245
times ranked

24011
citing authors

#	ARTICLE	IF	CITATIONS
1	Copper induces cell death by targeting lipoylated TCA cycle proteins. <i>Science</i> , 2022, 375, 1254-1261.	6.0	1,539
2	Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets. <i>Cancer Discovery</i> , 2015, 5, 1164-1177.	7.7	821
3	Integrative Genomic Analysis of Medulloblastoma Identifies a Molecular Subgroup That Drives Poor Clinical Outcome. <i>Journal of Clinical Oncology</i> , 2011, 29, 1424-1430.	0.8	609
4	HSF1 Drives a Transcriptional Program Distinct from Heat Shock to Support Highly Malignant Human Cancers. <i>Cell</i> , 2012, 150, 549-562.	13.5	602
5	Genomic sequencing of meningiomas identifies oncogenic SMO and AKT1 mutations. <i>Nature Genetics</i> , 2013, 45, 285-289.	9.4	532
6	Highly multiplexed immunofluorescence imaging of human tissues and tumors using t-CyCIF and conventional optical microscopes. <i>ELife</i> , 2018, 7, .	2.8	474
7	Partial V(D)J Recombination Activity Leads to Omenn Syndrome. <i>Cell</i> , 1998, 93, 885-896.	13.5	429
8	Exome sequencing identifies BRAF mutations in papillary craniopharyngiomas. <i>Nature Genetics</i> , 2014, 46, 161-165.	9.4	408
9	Rapid, Label-Free Detection of Brain Tumors with Stimulated Raman Scattering Microscopy. <i>Science Translational Medicine</i> , 2013, 5, 201ra119.	5.8	398
10	A HIF1 α Regulatory Loop Links Hypoxia and Mitochondrial Signals in Pheochromocytomas. <i>PLoS Genetics</i> , 2005, 1, e8.	1.5	394
11	Mechanisms and therapeutic implications of hypermutation in gliomas. <i>Nature</i> , 2020, 580, 517-523.	13.7	374
12	Derivation of Pre-X Inactivation Human Embryonic Stem Cells under Physiological Oxygen Concentrations. <i>Cell</i> , 2010, 141, 872-883.	13.5	367
13	G-Protein Signaling Through Tubby Proteins. <i>Science</i> , 2001, 292, 2041-2050.	6.0	352
14	The Human Tumor Atlas Network: Charting Tumor Transitions across Space and Time at Single-Cell Resolution. <i>Cell</i> , 2020, 181, 236-249.	13.5	334
15	V(D)J recombination defects in lymphocytes due to RAG mutations: severe immunodeficiency with a spectrum of clinical presentations. <i>Blood</i> , 2001, 97, 81-88.	0.6	324
16	Profiling Critical Cancer Gene Mutations in Clinical Tumor Samples. <i>PLoS ONE</i> , 2009, 4, e7887.	1.1	316
17	JAGGED1 Expression Is Associated with Prostate Cancer Metastasis and Recurrence. <i>Cancer Research</i> , 2004, 64, 6854-6857.	0.4	310
18	The Reprogramming of Tumor Stroma by HSF1 Is a Potent Enabler of Malignancy. <i>Cell</i> , 2014, 158, 564-578.	13.5	298

#	ARTICLE	IF	CITATIONS
19	High levels of nuclear heat-shock factor 1 (HSF1) are associated with poor prognosis in breast cancer. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 18378-18383.	3.3	275
20	Mitochondrial metabolism promotes adaptation to proteotoxic stress. Nature Chemical Biology, 2019, 15, 681-689.	3.9	275
21	Classifying Human Brain Tumors by Lipid Imaging with Mass Spectrometry. Cancer Research, 2012, 72, 645-654.	0.4	273
22	BRAF V600E Mutations Are Common in Pleomorphic Xanthoastrocytoma: Diagnostic and Therapeutic Implications. PLoS ONE, 2011, 6, e17948.	1.1	268
23	Ambient mass spectrometry for the intraoperative molecular diagnosis of human brain tumors. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 1611-1616.	3.3	251
24	Tight Coordination of Protein Translation and HSF1 Activation Supports the Anabolic Malignant State. Science, 2013, 341, 1238303.	6.0	234
25	Intraoperative mass spectrometry mapping of an onco-metabolite to guide brain tumor surgery. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 11121-11126.	3.3	230
26	Oncogenic PI3K mutations are as common as <i>AKT1</i> and <i>SMO</i> mutations in meningioma. Neuro-Oncology, 2016, 18, 649-655.	0.6	221
27	The Homeodomain Region of Rag-1 Reveals the Parallel Mechanisms of Bacterial and V(D)J Recombination. Cell, 1996, 87, 263-276.	13.5	219
28	MYB-QKI rearrangements in angiocentric glioma drive tumorigenicity through a tripartite mechanism. Nature Genetics, 2016, 48, 273-282.	9.4	214
29	Application of desorption electrospray ionization mass spectrometry imaging in breast cancer margin analysis. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 15184-15189.	3.3	207
30	Implication of Tubby Proteins as Transcription Factors by Structure-Based Functional Analysis. Science, 1999, 286, 2119-2125.	6.0	196
31	Genomic analysis of diffuse pediatric low-grade gliomas identifies recurrent oncogenic truncating rearrangements in the transcription factor <i>MYBL1</i> . Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 8188-8193.	3.3	188
32	Dramatic Response of BRAF V600E Mutant Papillary Craniopharyngioma to Targeted Therapy. Journal of the National Cancer Institute, 2016, 108, djv310.	3.0	182
33	Genomic characterization of human brain metastases identifies drivers of metastatic lung adenocarcinoma. Nature Genetics, 2020, 52, 371-377.	9.4	177
34	Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancer. Nature Communications, 2020, 11, 1459.	5.8	176
35	Embryonic Stem Cell Transcription Factor Signatures in the Diagnosis of Primary and Metastatic Germ Cell Tumors. American Journal of Surgical Pathology, 2007, 31, 836-845.	2.1	169
36	Taxonomy of breast cancer based on normal cell phenotype predicts outcome. Journal of Clinical Investigation, 2014, 124, 859-870.	3.9	164

#	ARTICLE	IF	CITATIONS
37	Comprehensive Study of the Clinical Phenotype of Germline <i>BAP1</i> Variant-Carrying Families Worldwide. <i>Journal of the National Cancer Institute</i> , 2018, 110, 1328-1341.	3.0	164
38	FokI requires two specific DNA sites for cleavage. <i>Journal of Molecular Biology</i> , 2001, 309, 69-78.	2.0	160
39	Phase II Study of Protracted Daily Temozolomide for Low-Grade Gliomas in Adults. <i>Clinical Cancer Research</i> , 2009, 15, 330-337.	3.2	147
40	Desorption Electrospray Ionization then MALDI Mass Spectrometry Imaging of Lipid and Protein Distributions in Single Tissue Sections. <i>Analytical Chemistry</i> , 2011, 83, 8366-8371.	3.2	142
41	Phase I/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas: North American Brain Tumor Consortium trial 04-02. <i>Neuro-Oncology</i> , 2014, 16, 567-578.	0.6	140
42	Rapid selection of cyclic peptides that reduce α -synuclein toxicity in yeast and animal models. <i>Nature Chemical Biology</i> , 2009, 5, 655-663.	3.9	130
43	Genomic landscape of high-grade meningiomas. <i>Npj Genomic Medicine</i> , 2017, 2, .	1.7	130
44	Controlled enzymatic production of astrocytic hydrogen peroxide protects neurons from oxidative stress via an Nrf2-independent pathway. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 17385-17390.	3.3	129
45	Using the Heat-Shock Response To Discover Anticancer Compounds that Target Protein Homeostasis. <i>ACS Chemical Biology</i> , 2012, 7, 340-349.	1.6	129
46	Increased expression of the immune modulatory molecule PD-L1 (CD274) in anaplastic meningioma. <i>Oncotarget</i> , 2015, 6, 4704-4716.	0.8	127
47	Targeting immunosuppressive macrophages overcomes PARP inhibitor resistance in BRCA1-associated triple-negative breast cancer. <i>Nature Cancer</i> , 2021, 2, 66-82.	5.7	126
48	<i>BAP1</i> mutations in high-grade meningioma: implications for patient care. <i>Neuro-Oncology</i> , 2017, 19, 1447-1456.	0.6	125
49	Chaperones as thermodynamic sensors of drug-target interactions reveal kinase inhibitor specificities in living cells. <i>Nature Biotechnology</i> , 2013, 31, 630-637.	9.4	120
50	Label-Free Neurosurgical Pathology with Stimulated Raman Imaging. <i>Cancer Research</i> , 2016, 76, 3451-3462.	0.4	119
51	Molecular imaging of drug transit through the blood-brain barrier with MALDI mass spectrometry imaging. <i>Scientific Reports</i> , 2013, 3, 2859.	1.6	118
52	Loss of tumor suppressor NF1 activates HSF1 to promote carcinogenesis. <i>Journal of Clinical Investigation</i> , 2012, 122, 3742-3754.	3.9	118
53	The RAG1 Homeodomain Recruits HMG1 and HMG2 To Facilitate Recombination Signal Sequence Binding and To Enhance the Intrinsic DNA-Bending Activity of RAG1-RAG2. <i>Molecular and Cellular Biology</i> , 1999, 19, 6532-6542.	1.1	112
54	Radiographic prediction of meningioma grade by semantic and radiomic features. <i>PLoS ONE</i> , 2017, 12, e0187908.	1.1	109

#	ARTICLE	IF	CITATIONS
55	HSP90 empowers evolution of resistance to hormonal therapy in human breast cancer models. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 18297-18302.	3.3	104
56	Genomic landscape of intracranial meningiomas. Journal of Neurosurgery, 2016, 125, 525-535.	0.9	104
57	An update on the CNS manifestations of neurofibromatosis type 2. Acta Neuropathologica, 2020, 139, 643-665.	3.9	102
58	MCMICRO: a scalable, modular image-processing pipeline for multiplexed tissue imaging. Nature Methods, 2022, 19, 311-315.	9.0	102
59	Increased expression of programmed death ligand 1 (PD-L1) in human pituitary tumors. Oncotarget, 2016, 7, 76565-76576.	0.8	100
60	Germline and somatic BAP1 mutations in high-grade rhabdoid meningiomas. Neuro-Oncology, 2017, 19, now235.	0.6	99
61	Targeting Pin1 renders pancreatic cancer eradicable by synergizing with immunochemotherapy. Cell, 2021, 184, 4753-4771.e27.	13.5	99
62	Neuropathology of a Case With Fatal CAR T-Cell-Associated Cerebral Edema. Journal of Neuropathology and Experimental Neurology, 2018, 77, 877-882.	0.9	95
63	Landscape of Genomic Alterations in Pituitary Adenomas. Clinical Cancer Research, 2017, 23, 1841-1851.	3.2	94
64	Qualifying antibodies for image-based immune profiling and multiplexed tissue imaging. Nature Protocols, 2019, 14, 2900-2930.	5.5	92
65	The Spatial Landscape of Progression and Immunoediting in Primary Melanoma at Single-Cell Resolution. Cancer Discovery, 2022, 12, 1518-1541.	7.7	87
66	Mass spectrometry imaging as a tool for surgical decision-making. Journal of Mass Spectrometry, 2013, 48, 1178-1187.	0.7	85
67	Antigen dominance hierarchies shape TCF1+ progenitor CD8 T cell phenotypes in tumors. Cell, 2021, 184, 4996-5014.e26.	13.5	84
68	A molecularly integrated grade for meningioma. Neuro-Oncology, 2022, 24, 796-808.	0.6	83
69	Detection of KIAA1549-BRAF Fusion Transcripts in Formalin-Fixed Paraffin-Embedded Pediatric Low-Grade Gliomas. Journal of Molecular Diagnostics, 2011, 13, 669-677.	1.2	81
70	Adjuvant radiation therapy, local recurrence, and the need for salvage therapy in atypical meningioma. Neuro-Oncology, 2014, 16, 1547-1553.	0.6	80
71	Updates in prognostic markers for gliomas. Neuro-Oncology, 2018, 20, vii17-vii26.	0.6	78
72	Successful Treatment of a Progressive BRAF V600E-Mutated Anaplastic Pleomorphic Xanthoastrocytoma With Vemurafenib Monotherapy. Journal of Clinical Oncology, 2016, 34, e87-e89.	0.8	77

#	ARTICLE	IF	CITATIONS
73	Omenn syndrome: a disorder of Rag1 and Rag2 genes. <i>Journal of Clinical Immunology</i> , 1999, 19, 87-97.	2.0	73
74	The RAG1/RAG2 Complex Constitutes a 3' Flap Endonuclease. <i>Molecular Cell</i> , 1999, 4, 935-947.	4.5	73
75	MALDI mass spectrometry imaging analysis of pituitary adenomas for near-real-time tumor delineation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 9978-9983.	3.3	73
76	ARID1A and TERT promoter mutations in dedifferentiated meningioma. <i>Cancer Genetics</i> , 2015, 208, 345-350.	0.2	73
77	Multiplexed immunofluorescence reveals potential PD-1/PD-L1 pathway vulnerabilities in craniopharyngioma. <i>Neuro-Oncology</i> , 2018, 20, 1101-1112.	0.6	67
78	Localized Metabolomic Gradients in Patient-Derived Xenograft Models of Glioblastoma. <i>Cancer Research</i> , 2020, 80, 1258-1267.	0.4	67
79	HSF1 phase transition mediates stress adaptation and cell fate decisions. <i>Nature Cell Biology</i> , 2020, 22, 151-158.	4.6	67
80	Compromising the 19S proteasome complex protects cells from reduced flux through the proteasome. <i>ELife</i> , 2015, 4, .	2.8	67
81	DMD genomic deletions characterize a subset of progressive/higher-grade meningiomas with poor outcome. <i>Acta Neuropathologica</i> , 2018, 136, 779-792.	3.9	66
82	N-terminal RAG1 frameshift mutations in Omenn's syndrome: Internal methionine usage leads to partial V(D)J recombination activity and reveals a fundamental role in vivo for the N-terminal domains. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2000, 97, 14572-14577.	3.3	65
83	Angiomatous meningiomas have a distinct genetic profile with multiple chromosomal polysomies including polysomy of chromosome 5. <i>Oncotarget</i> , 2014, 5, 10596-10606.	0.8	65
84	Sporadic hemangioblastomas are characterized by cryptic VHL inactivation. <i>Acta Neuropathologica Communications</i> , 2014, 2, 167.	2.4	65
85	A prognostic cytogenetic scoring system to guide the adjuvant management of patients with atypical meningioma. <i>Neuro-Oncology</i> , 2016, 18, 269-274.	0.6	64
86	Structure-Activity Relationships for Withanolides as Inducers of the Cellular Heat-Shock Response. <i>Journal of Medicinal Chemistry</i> , 2014, 57, 2851-2863.	2.9	63
87	Inhibiting HSP90 to Treat Cancer: A Strategy in Evolution. <i>Current Molecular Medicine</i> , 2012, 12, 1108-1124.	0.6	62
88	ENDOCRINE TUMORS: BRAF V600E mutations in papillary craniopharyngioma. <i>European Journal of Endocrinology</i> , 2016, 174, R139-R144.	1.9	61
89	Rapid MALDI mass spectrometry imaging for surgical pathology. <i>Npj Precision Oncology</i> , 2019, 3, 17.	2.3	59
90	Mutations in Conserved Regions of the Predicted RAG2 Kelch Repeats Block Initiation of V(D)J Recombination and Result in Primary Immunodeficiencies. <i>Molecular and Cellular Biology</i> , 2000, 20, 5653-5664.	1.1	58

#	ARTICLE	IF	CITATIONS
91	Eastern Equine Encephalitis in Children, Massachusetts and New Hampshire, USA, 1970–2010. <i>Emerging Infectious Diseases</i> , 2013, 19, 194-201.	2.0	58
92	Targeted treatment of papillary craniopharyngiomas harboring BRAF V600E mutations. <i>Cancer</i> , 2019, 125, 2910-2914.	2.0	58
93	Distinct genomic subclasses of high-grade/progressive meningiomas: NF2-associated, NF2-exclusive, and NF2-agnostic. <i>Acta Neuropathologica Communications</i> , 2020, 8, 171.	2.4	58
94	The genetic and biochemical basis of Omenn syndrome. <i>Immunological Reviews</i> , 2000, 178, 64-74.	2.8	56
95	Cross-reactivity of the BRAF VE1 antibody with epitopes in axonemal dyneins leads to staining of cilia. <i>Modern Pathology</i> , 2015, 28, 596-606.	2.9	55
96	Clinical multiplexed exome sequencing distinguishes adult oligodendroglial neoplasms from astrocytic and mixed lineage gliomas. <i>Oncotarget</i> , 2014, 5, 8083-8092.	0.8	55
97	Clinical targeted exome-based sequencing in combination with genome-wide copy number profiling: precision medicine analysis of 203 pediatric brain tumors. <i>Neuro-Oncology</i> , 2017, 19, now294.	0.6	54
98	Clinical Identification of Oncogenic Drivers and Copy-Number Alterations in Pituitary Tumors. <i>Endocrinology</i> , 2017, 158, 2284-2291.	1.4	53
99	A human breast atlas integrating single-cell proteomics and transcriptomics. <i>Developmental Cell</i> , 2022, 57, 1400-1420.e7.	3.1	50
100	Comparative Analysis of Germ Cell Transcription Factors in CNS Germinoma Reveals Diagnostic Utility of NANOG. <i>American Journal of Surgical Pathology</i> , 2006, 30, 1613-1618.	2.1	49
101	Clinical and radiographic response following targeting of BCAN-NTRK1 fusion in glioneuronal tumor. <i>Npj Precision Oncology</i> , 2017, 1, 5.	2.3	49
102	Targeted sequencing of SMO and AKT1 in anterior skull base meningiomas. <i>Journal of Neurosurgery</i> , 2017, 127, 438-444.	0.9	48
103	Suppression of 19S proteasome subunits marks emergence of an altered cell state in diverse cancers. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, 382-387.	3.3	47
104	Molecular typing of meningiomas by desorption electrospray ionization mass spectrometry imaging for surgical decision-making. <i>International Journal of Mass Spectrometry</i> , 2015, 377, 690-698.	0.7	46
105	Rapid discrimination of pediatric brain tumors by mass spectrometry imaging. <i>Journal of Neuro-Oncology</i> , 2018, 140, 269-279.	1.4	45
106	The impact of histopathology and NAB2–STAT6 fusion subtype in classification and grading of meningeal solitary fibrous tumor/hemangiopericytoma. <i>Acta Neuropathologica</i> , 2019, 137, 307-319.	3.9	44
107	Definition of Minimal Domains of Interaction Within the Recombination-Activating Genes 1 and 2 Recombinase Complex. <i>Journal of Immunology</i> , 2000, 164, 5826-5832.	0.4	43
108	CRX Is a Diagnostic Marker of Retinal and Pineal Lineage Tumors. <i>PLoS ONE</i> , 2009, 4, e7932.	1.1	43

#	ARTICLE	IF	CITATIONS
109	Clinical implementation of integrated whole-genome copy number and mutation profiling for glioblastoma. <i>Neuro-Oncology</i> , 2015, 17, 1344-1355.	0.6	40
110	Treatment of brain metastases in the modern genomic era. , 2017, 170, 64-72.		40
111	Expression profiles of 151 pediatric low-grade gliomas reveal molecular differences associated with location and histological subtype. <i>Neuro-Oncology</i> , 2015, 17, 1486-1496.	0.6	39
112	Highly multiplexed immunofluorescence images and single-cell data of immune markers in tonsil and lung cancer. <i>Scientific Data</i> , 2019, 6, 323.	2.4	39
113	The Effect of Me2+ Cofactors at the Initial Stages of V(D)J Recombination. <i>Journal of Biological Chemistry</i> , 1998, 273, 16325-16331.	1.6	38
114	Intraoperative Magnetic Resonance Imaging in Intracranial Glioma Resection: A Single-Center, Retrospective Blinded Volumetric Study. <i>World Neurosurgery</i> , 2015, 84, 528-536.	0.7	38
115	Activity of PD-1 blockade with nivolumab among patients with recurrent atypical/anaplastic meningioma: phase II trial results. <i>Neuro-Oncology</i> , 2022, 24, 101-113.	0.6	38
116	Rebalancing Protein Homeostasis Enhances Tumor Antigen Presentation. <i>Clinical Cancer Research</i> , 2019, 25, 6392-6405.	3.2	37
117	Neuronal differentiation and cell-cycle programs mediate response to BET-bromodomain inhibition in MYC-driven medulloblastoma. <i>Nature Communications</i> , 2019, 10, 2400.	5.8	37
118	MITI minimum information guidelines for highly multiplexed tissue images. <i>Nature Methods</i> , 2022, 19, 262-267.	9.0	37
119	The Master Regulator of the Cellular Stress Response (HSF1) Is Critical for Orthopoxvirus Infection. <i>PLoS Pathogens</i> , 2014, 10, e1003904.	2.1	35
120	Mismatch Repair Deficiency in High-Grade Meningioma: A Rare but Recurrent Event Associated With Dramatic Immune Activation and Clinical Response to PD-1 Blockade. <i>JCO Precision Oncology</i> , 2018, 2018, 1-12.	1.5	35
121	A Deregulated HOX Gene Axis Confers an Epigenetic Vulnerability in KRAS-Mutant Lung Cancers. <i>Cancer Cell</i> , 2020, 37, 705-719.e6.	7.7	35
122	Temporal and spatial topography of cell proliferation in cancer. <i>Nature Cell Biology</i> , 2022, 24, 316-326.	4.6	34
123	Frequent inactivating mutations of the PBAF complex gene PBRM1 in meningioma with papillary features. <i>Acta Neuropathologica</i> , 2020, 140, 89-93.	3.9	32
124	Single-cell tumor-immune microenvironment of BRCA1/2 mutated high-grade serous ovarian cancer. <i>Nature Communications</i> , 2022, 13, 835.	5.8	32
125	Molecular Cloning and Characterization of a Mouse Homolog of Bacterial ClpX, a Novel Mammalian Class II Member of the Hsp100/Clp Chaperone Family. <i>Journal of Biological Chemistry</i> , 1999, 274, 16311-16319.	1.6	31
126	Multiplex Amplification Coupled with COLD-PCR and High Resolution Melting Enables Identification of Low-Abundance Mutations in Cancer Samples with Low DNA Content. <i>Journal of Molecular Diagnostics</i> , 2011, 13, 220-232.	1.2	31

#	ARTICLE	IF	CITATIONS
127	Phase 2 study of pembrolizumab in patients with recurrent and residual high-grade meningiomas. <i>Nature Communications</i> , 2022, 13, 1325.	5.8	31
128	Decreased FOXJ1 expression and its ciliogenesis programme in aggressive ependymoma and choroid plexus tumours. <i>Journal of Pathology</i> , 2016, 238, 584-597.	2.1	29
129	DNA Fragmentation Simulation Method (FSM) and Fragment Size Matching Improve aCGH Performance of FFPE Tissues. <i>PLoS ONE</i> , 2012, 7, e38881.	1.1	28
130	Diagnosis and management of craniopharyngiomas in the era of genomics and targeted therapy. <i>Neurosurgical Focus</i> , 2016, 41, E2.	1.0	28
131	Response and Mechanisms of Resistance to Larotrectinib and Selitrectinib in Metastatic Undifferentiated Sarcoma Harboring Oncogenic Fusion of NTRK1. <i>JCO Precision Oncology</i> , 2020, 4, 79-90.	1.5	27
132	Palbociclib demonstrates intracranial activity in progressive brain metastases harboring cyclin-dependent kinase pathway alterations. <i>Nature Cancer</i> , 2021, 2, 498-502.	5.7	26
133	Profiling of adrenocorticotrophic hormone and arginine vasopressin in human pituitary gland and tumor thin tissue sections using droplet-based liquid-microjunction surface-sampling-HPLC-ESI-MS-MS. <i>Analytical and Bioanalytical Chemistry</i> , 2015, 407, 5989-5998.	1.9	24
134	Checkpoint inhibition in meningiomas. <i>Immunotherapy</i> , 2016, 8, 721-731.	1.0	22
135	Minerva: a light-weight, narrative image browser for multiplexed tissue images. <i>Journal of Open Source Software</i> , 2020, 5, 2579.	2.0	22
136	Osteoglycin promotes meningioma development through downregulation of NF2 and activation of mTOR signaling. <i>Cell Communication and Signaling</i> , 2017, 15, 34.	2.7	21
137	Pre- and Postoperative Neratinib for HER2-Positive Breast Cancer Brain Metastases: Translational Breast Cancer Research Consortium 022. <i>Clinical Breast Cancer</i> , 2020, 20, 145-151.e2.	1.1	21
138	Artifacts to avoid while taking advantage of top-down mass spectrometry based detection of protein S-nitrosylation. <i>Proteomics</i> , 2014, 14, 1152-1157.	1.3	20
139	Identification and Therapeutic Targeting of GPR20, Selectively Expressed in Gastrointestinal Stromal Tumors, with DS-6157a, a First-in-Class Antibody-Drug Conjugate. <i>Cancer Discovery</i> , 2021, 11, 1508-1523.	7.7	20
140	Atypical presentation of cerebral schistosomiasis four years after exposure to <i>Schistosoma mansoni</i> . <i>Epilepsy & Behavior Case Reports</i> , 2014, 2, 80-85.	1.5	19
141	Fatal Eastern Equine Encephalitis in a Patient on Maintenance Rituximab: A Case Report. <i>Open Forum Infectious Diseases</i> , 2017, 4, ofx021.	0.4	18
142	Alliance A071601: Phase II trial of BRAF/MEK inhibition in newly diagnosed papillary craniopharyngiomas. <i>Journal of Clinical Oncology</i> , 2021, 39, 2000-2000.	0.8	18
143	Normal cell phenotypes of breast epithelial cells provide the foundation of a breast cancer taxonomy. <i>Expert Review of Anticancer Therapy</i> , 2014, 14, 1385-1389.	1.1	17
144	Alliance A071401: Phase II trial of FAK inhibition in meningiomas with somatic NF2 mutations. <i>Journal of Clinical Oncology</i> , 2020, 38, 2502-2502.	0.8	17

#	ARTICLE	IF	CITATIONS
145	Narrative online guides for the interpretation of digital-pathology images and tissue-atlas data. <i>Nature Biomedical Engineering</i> , 2022, 6, 515-526.	11.6	17
146	Potential evolution of neurosurgical treatment paradigms for craniopharyngioma based on genomic and transcriptomic characteristics. <i>Neurosurgical Focus</i> , 2016, 41, E3.	1.0	16
147	Distinct patterns of primary and motile cilia in Rathke's cleft cysts and craniopharyngioma subtypes. <i>Modern Pathology</i> , 2016, 29, 1446-1459.	2.9	15
148	Novel MPZ mutations and congenital hypomyelinating neuropathy. <i>Neuromuscular Disorders</i> , 2010, 20, 725-729.	0.3	14
149	HAND1 and BARX1 Act as Transcriptional and Anatomic Determinants of Malignancy in Gastrointestinal Stromal Tumor. <i>Clinical Cancer Research</i> , 2021, 27, 1706-1719.	3.2	14
150	New molecular targets in meningiomas: the present and the future. <i>Current Opinion in Neurology</i> , 2018, 31, 740-746.	1.8	13
151	Telomere length alterations and ATRX/DAXX loss in pituitary adenomas. <i>Modern Pathology</i> , 2020, 33, 1475-1481.	2.9	13
152	HSF2 cooperates with HSF1 to drive a transcriptional program critical for the malignant state. <i>Science Advances</i> , 2022, 8, eabj6526.	4.7	13
153	Clinical utility of targeted next-generation sequencing assay in IDH-wildtype glioblastoma for therapy decision-making. <i>Neuro-Oncology</i> , 2022, 24, 1140-1149.	0.6	13
154	Recombinase activating gene enzymes of lymphocytes. <i>Current Opinion in Hematology</i> , 2001, 8, 41-46.	1.2	12
155	Sporadic multiple meningiomas harbor distinct driver mutations. <i>Acta Neuropathologica Communications</i> , 2021, 9, 8.	2.4	12
156	Nuclear CRX and FOXJ1 Expression Differentiates Non-Germ Cell Pineal Region Tumors and Supports the Ependymal Differentiation of Papillary Tumor of the Pineal Region. <i>American Journal of Surgical Pathology</i> , 2017, 41, 1410-1421.	2.1	11
157	Interim clinical trial analysis of intraoperative mass spectrometry for breast cancer surgery. <i>Npj Breast Cancer</i> , 2021, 7, 116.	2.3	10
158	Meningioma transcription factors link cell lineage with systemic metabolic cues. <i>Neuro-Oncology</i> , 2018, 20, 1331-1343.	0.6	9
159	Scope2Screen: Focus+Context Techniques for Pathology Tumor Assessment in Multivariate Image Data. <i>IEEE Transactions on Visualization and Computer Graphics</i> , 2022, 28, 259-269.	2.9	9
160	Intramedullary neuroma of the cervicomedullary junction. <i>Journal of Neurosurgery: Spine</i> , 2006, 5, 362-366.	0.9	8
161	SYLARAS: A Platform for the Statistical Analysis and Visual Display of Systemic Immunoprofiling Data and Its Application to Glioblastoma. <i>Cell Systems</i> , 2020, 11, 272-285.e9.	2.9	8
162	Case-Based Review: meningioma. <i>Neuro-Oncology Practice</i> , 2016, 3, 120-134.	1.0	6

#	ARTICLE	IF	CITATIONS
163	Rapid Mass Spectrometry Imaging to Assess the Biochemical Profile of Pituitary Tissue for Potential Intraoperative Usage. <i>Advances in Cancer Research</i> , 2017, 134, 257-282.	1.9	6
164	CTNI-12. PRELIMINARY RESULTS OF THE ABEMACICLIB ARM IN THE INDIVIDUALIZED SCREENING TRIAL OF INNOVATIVE GLIOBLASTOMA THERAPY (INSIGHT): A PHASE II PLATFORM TRIAL USING BAYESIAN ADAPTIVE RANDOMIZATION. <i>Neuro-Oncology</i> , 2020, 22, ii44-ii44.	0.6	5
165	Anaplastic variant of medulloblastoma mimicking a vestibular schwannoma. <i>Journal of Neuro-Oncology</i> , 2006, 81, 49-51.	1.4	4
166	Mycosis Fungoides With Leptomeningeal Involvement. <i>Journal of Clinical Oncology</i> , 2007, 25, 5658-5661.	0.8	4
167	Uncovering the links between systemic hormones and oncogenic signaling in the pathogenesis of meningioma. <i>Annals of Oncology</i> , 2018, 29, 537-540.	0.6	4
168	Multimodal platform for assessing drug distribution and response in clinical trials. <i>Neuro-Oncology</i> , 2022, 24, 64-77.	0.6	4
169	CTNI-05. PRELIMINARY RESULTS OF THE NERATINIB ARM IN THE INDIVIDUALIZED SCREENING TRIAL OF INNOVATIVE GLIOBLASTOMA THERAPY (INSIGHT): A PHASE II PLATFORM TRIAL USING BAYESIAN ADAPTIVE RANDOMIZATION. <i>Neuro-Oncology</i> , 2021, 23, vi59-vi59.	0.6	4
170	Post-irradiation meningioma with sarcoidosis. <i>Journal of Neuro-Oncology</i> , 2007, 82, 271-272.	1.4	3
171	Susan Lindquist (1949â€“2016). <i>Science</i> , 2016, 354, 974-974.	6.0	3
172	A case of molecularly profiled extraneural medulloblastoma metastases in a child. <i>BMC Medical Genetics</i> , 2018, 19, 10.	2.1	3
173	Skull Base Tumors: Neuropathology and Clinical implications. <i>Neurosurgery</i> , 2021, 90, .	0.6	3
174	Transcriptomic and Genomic Analyses of Human Craniopharyngioma. , 2017, , 27-39.		3
175	CTNI-11. CC-115 IN NEWLY DIAGNOSED MGMT UNMETHYLATED GLIOBLASTOMA IN THE INDIVIDUALIZED SCREENING TRIAL OF INNOVATIVE GLIOBLASTOMA THERAPY (INSIGHT): A PHASE II RANDOMIZED BAYESIAN ADAPTIVE PLATFORM TRIAL. <i>Neuro-Oncology</i> , 2020, 22, ii43-ii44.	0.6	3
176	SUâ€“207Bâ€“02: Early Grade Classification in Meningioma Patients Combining Radiomics and Semantics Data. <i>Medical Physics</i> , 2016, 43, 3348-3349.	1.6	3
177	Integrating Genomics Into Neuro-Oncology Clinical Trials and Practice. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2018, 38, 148-157.	1.8	2
178	CRAN-11. MULTIPLEXED IMMUNOFLOURESCENCE REVEALS POTENTIAL PD-1/PD-L1 PATHWAY VULNERABILITIES IN CRANIOPHARYNGIOMA. <i>Neuro-Oncology</i> , 2018, 20, i39-i39.	0.6	2
179	Orbital leiomyosarcoma metastasis presenting prior to diagnosis of the primary tumor. <i>Digital Journal of Ophthalmology: DJO</i> , 2017, 23, 113-117.	0.2	2
180	Relapsing Tumefactive Lesion in an Adult with Medulloblastoma Previously Treated with Chemoradiotherapy and Stem Cell Transplant. <i>Pathology and Oncology Research</i> , 2012, 18, 539-543.	0.9	1

#	ARTICLE	IF	CITATIONS
181	RARE-08. GRADING CONSIDERATIONS FOR MENINGEAL SOLITARY FIBROUS TUMOR/HEMANGIOPERICYTOMA. <i>Neuro-Oncology</i> , 2018, 20, vi237-vi238.	0.6	1
182	GENE-63. GENOMIC CHARACTERIZATION OF HUMAN BRAIN METASTASES IDENTIFIES NOVEL DRIVERS OF LUNG ADENOCARCINOMA PROGRESSION. <i>Neuro-Oncology</i> , 2019, 21, vi111-vi111.	0.6	1
183	The Spatial Landscape of Progression and Immunoediting in Primary Melanoma at Single Cell Resolution. <i>SSRN Electronic Journal</i> , 0, , .	0.4	1
184	Prognostication for meningiomas: H3K27me3 to the rescue?. <i>Neuro-Oncology</i> , 2021, 23, 1218-1219.	0.6	1
185	Abstract 4: Temporal and spatial topography of cell proliferation in cancer. , 2021, , .		1
186	Radiographic Prediction of Meningioma Grade and Genomic Profile. <i>Journal of Neurological Surgery, Part B: Skull Base</i> , 2017, 78, S1-S156.	0.4	1
187	860â€¦Targeting immunosuppressive macrophages overcomes PARP-inhibitor resistance in BRCA1-associated triple-negative breast cancer. , 2020, , .		1
188	Combined whole genome copy number genotyping and multiplex somatic mutation profiling of FFPE brain tumor specimens for clinical diagnosis and trial selection.. <i>Journal of Clinical Oncology</i> , 2013, 31, 2030-2030.	0.8	1
189	Molecular characterization and management of secondary resistance to serial TRK inhibitors.. <i>Journal of Clinical Oncology</i> , 2019, 37, e22547-e22547.	0.8	1
190	ALLELE: A consortium for prospective genomics and functional diagnostics to guide patient care and trial analysis in newly-diagnosed glioblastoma.. <i>Journal of Clinical Oncology</i> , 2018, 36, 2003-2003.	0.8	1
191	DIPG-44. H3K27-altered diffuse midline gliomas with secondary driver molecular alterations. <i>Neuro-Oncology</i> , 2022, 24, i28-i28.	0.6	1
192	INNV-13. ALLELE: A CONSORTIUM FOR PROSPECTIVE GENOMICS AND FUNCTIONAL DIAGNOSTICS TO GUIDE PATIENT CARE AND TRIAL ANALYSIS IN NEWLY-DIAGNOSED GLIOBLASTOMA. <i>Neuro-Oncology</i> , 2018, 20, vi140-vi141.	0.6	0
193	MBRS-01. A CASE OF MOLECULARLY PROFILED EXTRANEURAL MEDULLOBLASTOMA METASTASES IN A CHILD. <i>Neuro-Oncology</i> , 2018, 20, i128-i128.	0.6	0
194	PATH-16. MOLECULAR PATHOLOGY AND CLINICAL CHARACTERISTICS OF MMR DEFICIENCY (MMRd) IN DIFFUSE GLIOMAS. <i>Neuro-Oncology</i> , 2018, 20, vi161-vi161.	0.6	0
195	MEDU-37. NEURONAL DIFFERENTIATION AND CELL-CYCLE PROGRAMS MEDIATE RESPONSE AND RESISTANCE TO BET-BROMODOMAIN INHIBITION IN MYC-DRIVEN MEDULLOBLASTOMA. <i>Neuro-Oncology</i> , 2019, 21, ii111-ii111.	0.6	0
196	DRES-08. CLINICAL SIGNIFICANCE OF HYPERMUTATION IN GLIOMAS. <i>Neuro-Oncology</i> , 2019, 21, vi73-vi73.	0.6	0
197	RARE-04. TARGETED TREATMENT OF PAPILLARY CRANIOPHARYNGIOMAS HARBORING BRAFV600E MUTATIONS. <i>Neuro-Oncology</i> , 2019, 21, vi222-vi222.	0.6	0
198	CMET-33. PHASE II STUDY OF PALBOCICLIB IN BRAIN METASTASES HARBORING CDK PATHWAY ALTERATIONS. <i>Neuro-Oncology</i> , 2019, 21, vi58-vi59.	0.6	0

#	ARTICLE	IF	CITATIONS
199	46. PAN-CANCER ANALYSIS OF ORTHOTOPIC PATIENT DERIVED XENOGRAFTS FROM BRAIN METASTASES. <i>Neuro-Oncology Advances</i> , 2020, 2, ii9-ii9.	0.4	0
200	Temporal and spatial topography of cell proliferation in cancer.. <i>Journal of Clinical Oncology</i> , 2021, 39, 3122-3122.	0.8	0
201	Abstract 122: Highly multiplexed, spatially-resolved tissue imaging of genetically engineered mouse models of cancer to discover and characterize immune regulators of tumorigenesis. , 2021, , .		0
202	Abstract 1816: Phenogenomic characterization of immunomodulatory purinergic signaling in glioblastoma. , 2021, , .		0
203	P04.09 Frequent inactivating mutations of PBRM1 in meningioma with papillary features. <i>Neuro-Oncology</i> , 2021, 23, ii20-ii20.	0.6	0
204	Genomic characterization of meningiomas.. <i>Journal of Clinical Oncology</i> , 2012, 30, 2020-2020.	0.8	0
205	Abstract B067: Taxonomy of breast cancer based on normal cell phenotype and ontology. , 2013, , .		0
206	Integrative whole-genome copy number analysis and mutation profiling of FFPE brain tumor specimens and potential in designing multi-arm clinical trials.. <i>Journal of Clinical Oncology</i> , 2014, 32, 11098-11098.	0.8	0
207	Craniopharyngioma Pathogenesis and Implications for Medical Management. <i>Journal of Neurological Surgery, Part B: Skull Base</i> , 2017, 78, S1-S156.	0.4	0
208	Genomic Landscape of High-grade Meningiomas. <i>Journal of Neurological Surgery, Part B: Skull Base</i> , 2017, 78, S1-S156.	0.4	0
209	Molecular Taxonomy of Meningioma. , 2020, 81, .		0
210	RARE-07. THE LANDSCAPE OF GENOMIC ALTERATIONS IN ADAMANTINOMATOUS CRANIOPHARYNGIOMAS. <i>Neuro-Oncology</i> , 2020, 22, iii443-iii443.	0.6	0
211	PATH-37. DISTINCT GENOMIC SUBCLASSES OF HIGH-GRADE/PROGRESSIVE MENINGIOMAS: NF2-ASSOCIATED, NF2-EXCLUSIVE, AND NF2-AGNOSTIC. <i>Neuro-Oncology</i> , 2021, 23, vi123-vi123.	0.6	0
212	CTIM-30. PHASE II TRIAL OF PEMBROLIZUMAB IN RECURRENT AND RESIDUAL HIGH-GRADE MENINGIOMAS. <i>Neuro-Oncology</i> , 2021, 23, vi57-vi57.	0.6	0
213	CTNI-53. RADIATION TREATMENT VOLUMES BEFORE AND AFTER BRAF/MEK THERAPY IN NEWLY DIAGNOSED PAPILLARY CRANIOPHARYNGIOMAS: A CORRELATIVE ANALYSIS OF THE ALLIANCE A071601 PHASE II TRIAL. <i>Neuro-Oncology</i> , 2021, 23, vi72-vi72.	0.6	0
214	PATH-03. CLINICAL UTILITY OF NEXT GENERATION SEQUENCING IN IDH-WILDTYPE GLIOBLASTOMA: THE DANA-FARBER CANCER INSTITUTE EXPERIENCE. <i>Neuro-Oncology</i> , 2020, 22, ii164-ii164.	0.6	0
215	TMOD-03. PAN-CANCER ANALYSIS OF ORTHOTOPIC PATIENT DERIVED XENOGRAFTS FROM BRAIN METASTASES. <i>Neuro-Oncology</i> , 2020, 22, ii228-ii228.	0.6	0
216	TAMI-45. PHENOGENOMIC CHARACTERIZATION OF IMMUNOMODULATORY PURINERGIC SIGNALING IN GLIOBLASTOMA. <i>Neuro-Oncology</i> , 2020, 22, ii222-ii223.	0.6	0

#	ARTICLE	IF	CITATIONS
217	PATH-35. A SCALABLE MOLECULARLY INTEGRATED CLASSIFIER FOR MENINGIOMA OUTPERFORMS WHO CLASSIFICATION. <i>Neuro-Oncology</i> , 2020, 22, ii172-ii172.	0.6	0
218	Molecular and Clinical Characterization of Radiation-Induced Meningiomas. <i>Journal of Neurological Surgery, Part B: Skull Base</i> , 2022, 83, .	0.4	0
219	Abstract P2-07-13: High-dimensional, single-cell analysis and transcriptional profiling reveal novel correlatives of response to PARP inhibition plus PD-1 blockade in triple-negative breast cancer. <i>Cancer Research</i> , 2022, 82, P2-07-13-P2-07-13.	0.4	0